BJMO - volume 11, issue 4, september 2017
Tom Feys MBA, MSc
The melanoma abstracts discussed in this highlights report will focus on three main themes. First, three abstracts will be discussed addressing adjuvant therapy in patients with high-risk melanoma. Secondly, long-term data were presented of a phase III study assessing pembrolizumab in ipilimumab-naïve advanced melanoma patients, followed by the 5-year overall survival (OS) data of a study with dabrafenib and trametinib in BRAFV600 mutant metastatic melanoma. The third and last part of this summary will discuss the data of three clinical studies looking into the treatment of melanoma patients with brain metastasis. For a more complete overview of melanoma data presented at ASCO 2017 we would like to refer to the official congress website (www.am.asco.org).
Read moreBJMO - volume 11, issue 4, september 2017
J. Vansteenkiste MD, PhD, E. Wauters MD, PhD
At ASCO 2017, 195 abstracts in the feld of respiratory oncology were presented (169 in 2016): 22 oral presentations (including 4 in a clinical science symposium), 24 poster discussion items, and 149 posters. In this summary, most attention will go to phase III randomized controlled trials (RCTs) and innovative data that are, or may become, relevant for the practicing clinician. As this report is only the “extract of the abstracts”, the reader is referred to the respective abstracts published in J Clin Oncol volume 35 Suppl 15, 2017 (abstracts #8500–8586 and #9000–9107 and available on-line at https://meetinglibrary.asco.org/
Read moreBJMO - volume 11, issue 4, september 2017
Tom Feys MBA, MSc, H. Wildiers MD, PhD
This report will discuss a selection of key studies related to breast cancer discussed during the 2017 annual meeting of the American Society of Clinical Oncology. ASCO 2017 featured important new data generated with CDK4/6 inhibitors in patients with advanced breast cancer and included several abstracts considering the potential of PD-L1 inhibition for breast cancer. In addition to this, updates of several large phase III studies, including MARIANNE, ALLTO and APHINITY were presented. For a more complete overview of breast cancer news presented at ASCO 2017, we refer to the ASCO annual meeting website (https://meetings.asco.org/am/register-submit-abstracts).
Read moreBJMO - volume 11, issue 4, september 2017
P. Specenier MD, PhD
BJMO - volume 11, issue 4, september 2017
J. Kerger MD
BJMO - volume 11, issue 3, may 2017
W. Lybaert MD, M. Simoens , Wim Demey MD, F. van Fraeyenhove MD, T. Vandamme MD, PhD, L. De Backer , M. Peeters MD, PhD
Barcelona, 8-10 March 2017.
(BELG J MED ONCOL 2017;11(3):129–133)
Read moreBJMO - volume 11, issue 3, may 2017
Tom Feys MBA, MSc
From 12–15th March, the Society of Gynecological Oncology hosted its 48th annual meeting. The meeting continues to be one of the key educational and scientific events for physicians treating and caring for women with gynaecologic cancer. This summary will discuss some of the key studies presented during the meeting, with a focus on medical oncology. For a complete overview of abstracts presented in National Harbor we refer to the Society of Gynecological Oncology website: www.sgo.org.
(BELG J MED ONCOL 2017;11(3):134–137)
Read more
Top
